Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Saag, Kenneth G. [1 ]
de Villiers, Tobie [2 ,3 ]
Alexandersen, Peter [4 ]
Jacobe, Heidi [5 ]
Kovarik, Carrie [6 ]
Werth, Victoria P. [7 ]
Leung, Albert [8 ]
Desai-Merchant, Avani [8 ]
Mattaliano, Julie [8 ]
Gurner, Deborah [8 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Rheumatol & Immunol, Birmingham, AL 35294 USA
[2] Univ Stellenbosch, Mediclin Panorama, Cape Town, South Africa
[3] Univ Stellenbosch, Dept Obstet & Gynecol, Cape Town, South Africa
[4] Ctr Clin & Basic Res, Vejle, Denmark
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA
[6] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[7] Philadelphia VAMC, Philadelphia, PA USA
[8] Merck & Co Inc, Kenilworth, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1026
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Eight-Year Results from the Freedom Extension, Phase 3 Clinical Trial
    Lewiecki, E. Michael
    Papapoulos, Socrates
    Lippuner, Kurt
    Roux, Christian
    Lin, Celia J. F.
    Kendler, David L.
    Brandi, Maria L.
    Czerwinski, Edward
    Franek, Edward
    Lakatos, Peter
    Minisola, Salvatore
    Reginster, Jean-Yves
    Jensen, Soren
    Daizadeh, Nadia
    Wang, Andrea
    Gavin, Mary
    Wagman, Rachel B.
    Bone, Henry G.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [32] EFFECTS OF ABALOPARATIDE ON VERTEBRAL, NONVERTEBRAL, MAJOR OSTEOPOROTIC AND CLINICAL FRACTURE INCIDENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS OF THE PHASE 3 ACTIVE TRIAL
    Fitzpatrick, L. A.
    Miller, P.
    Cosman, F.
    Black, D.
    Lau, E.
    Zerbini, C. A. F.
    Riis, B. J.
    Christiansen, C.
    Williams, G.
    Hu, M. Y.
    Hattersley, G.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S39 - S39
  • [33] Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, J.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [34] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
    Bone, Henry G.
    Wagman, Rachel B.
    Brandi, Maria L.
    Brown, Jacques P.
    Chapurlat, Roland
    Cummings, Steven R.
    Czerwinski, Edward
    Fahrleitner-Pammer, Astrid
    Kendler, David L.
    Lippuner, Kurt
    Reginster, Jean-Yves
    Roux, Christian
    Malouf, Jorge
    Bradley, Michelle N.
    Daizadeh, Nadia S.
    Wang, Andrea
    Dakin, Paula
    Pannacciulli, Nicola
    Dempster, David W.
    Papapoulos, Socrates
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07): : 513 - 523
  • [35] Mineralization Density Distribution of Postmenopausal Osteoporotic Bone Is Restored to Normal After Long-Term Alendronate Treatment: qBEI and sSAXS Data From the Fracture Intervention Trial Long-Term Extension (FLEX)
    Roschger, P.
    Lombardi, A.
    Misof, B. M.
    Maier, G.
    Fratzl-Zelman, N.
    Fratzl, P.
    Klaushofer, K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) : 48 - 55
  • [36] Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
    Ensrud, KE
    Barrett-Connor, EL
    Schwartz, A
    Santora, AC
    Bauer, DC
    Suryawanshi, S
    Feldstein, A
    Haskell, WL
    Hochberg, MC
    Torner, JC
    Lombardi, A
    Black, DM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1259 - 1269
  • [37] Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab. Results from the Pivotal Phase 3 Fracture Study Extension
    Watts, Nelson B.
    Grbic, John T.
    McClung, Michael
    Papapoulos, Socrates
    Kendler, David
    Teglbjaerg, Christence S.
    O'Connor, Lawrence
    Wagman, Rachel B.
    Ng, Eric
    Daizadeh, Nadia S.
    Ho, Pei-Ran
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S407 - S407
  • [38] Evaluation of Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab: Results From the Pivotal Phase 3 Fracture Study Extension.
    Watts, Nelson B.
    Grbic, John T.
    McClung, Michael
    Papapoulos, Socrates
    Kendler, David
    Teglbjaerg, Christence S.
    O'Connor, Lawrence
    Wagman, Rachel B.
    Ng, Eric
    Daizadeh, Nadia S.
    Ho, Pei-Ran
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S112 - S112
  • [39] Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older: ACTIVExtend Phase 3 Trial
    Greenspan, S.
    Fitzpatrick, L. A.
    Mitlak, B.
    Wang, Y.
    Harvey, N.
    Deal, C.
    Cosman, F.
    McClung, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 : S219 - S219
  • [40] TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS USING PTH(1-84): SUSTAINED FRACTURE PREVENTION, INCREASED BONE MINERAL DENSITY AND LONG-TERM SAFETY
    Karachalios, T.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 186 - 186
12345